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ABSTRACT 
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Takotsubo cardiomyopathy (TTC) has generally been regarded as a relatively transient 
disorder, characterised by reversible regional left ventricular systolic dysfunction. However, 
the majority of TTC patients experience prolonged lassitude/dyspnoea following acute 
attacks. While this might reflect continued emotional stress, myocardial inflammation and 
accentuated BNP release persist for at least 3 months. We therefore tested the hypotheses that 
(i) this continued inflammation is associated with persistent contractile dysfunction and (ii) 
consequent impairment of quality of life. Echocardiographic parameters [global longitudinal 
strain (GLS), longitudinal strain rate (LSR) and peak apical twist (AT)] were compared 
acutely and after 3 months in 36 female TTC patients and 19 age-matched female controls. 
Furthermore, correlations were sought between putative functional anomalies, inflammatory 
markers (T2 score on CMR, plasma NT-proBNP and hs-CRP levels), and the physical 
composite component of SF36 score (SF36-PCS). Among TTC cases, LVEF returned to 
normal within 3 months. GLS, LSR and AT improved significantly over 3 months’ recovery, 
but GLS remained reduced compared to controls even at follow-up (-17.9 ± 3.1% vs. -20.0 ± 
1.8%, p =0.003). Impaired GLS at 3 months was associated both with persistent NT-proBNP 
elevation (p = 0.03) and reduced SF36-PCS at ≥ 3 months (p = 0.04). In conclusion, despite 
normalization of LVEF, GLS remains impaired for at least 3 months, possibly as a result of 
residual myocardial inflammation. Furthermore, perception of impaired physical exercise 
capacity ≥ 3 months post TTC may be explained by persistent myocardial dysfunction. 
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MAIN TEXT 
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Takotsubo cardiomyopathy (TTC), also known as acute stress-induced 
cardiomyopathy, apical ballooning syndrome and “broken heart syndrome”, is a form of 
regional left ventricular systolic dysfunction most commonly seen in aging women after 
physical or emotional stress1-4, which can be attributed to a dysfunctional myocardial reaction 
to high concentrations of catecholamines 5-7. The classical course of TTC is “spontaneously 
reversible” left ventricular (LV) systolic dysfunction: initially hypokinetic/akinetic (usually 
apical) regions recover to apparently normal wall motion within days in most cases 8,9. 
However, recent clinical studies report persistence of symptoms well beyond this 10, while 
myocardial inflammation persists on LV biopsy 11 and myocardial edema on MRI 12 3 months 
after acute attacks. Similarly, the associated (inflammatory) release of BNP/NT-proBNP 
persists for at least that duration13. We have now performed an echocardiographic comparison 
of TTC and matched control subjects, in order to test two hypotheses: (1) that LV systolic 
function remains abnormal 3 months post TTC, despite normal LVEF, reflecting underlying 
myocardial inflammation, and (2) that the extent of putative LV dysfunction after 3 months 
correlates with symptomatic limitation of physical performance.  
Methods 
TTC patients were eligible for inclusion on the basis of an acute diagnosis, according 
to the Mayo Clinic criteria 14 including: (1)  a presentation with abnormalities of ST 
segments/T waves, with or without chest  pain or dyspnoea, (2) a sustained elevation of 
cardiac troponin levels, (3) demonstration of a characteristic wall motion abnormality, not 
confined to a single epicardial coronary territory and the exclusion of obstructive coronary 
disease, via selective coronary angiography, in the territory subserving the regional wall 
motion abnormality. Exclusion criteria were pre-existing LV or valvular disease, 
phaeochromocytoma and myocarditis, each of which was prospectively considered. 
Age- and gender matched controls were recruited by advertisement and were eligible in the 
absence of known cardiac disease. The study complies with the Declaration of Helsinki and 
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was approved by the institutional ethics of human research committee. All participants in 
each group provided written informed consent. 
Echocardiography was performed, utilizing a Vivid 7 echocardiography machine) 
with a M5 ultrasound transducer (GEHVingmed, Horton, Norway. In patients with TTC, 
echocardiography was performed at the time of initial diagnosis, 10 days and 3 months 
thereafter. Standardised echocardiographic data included pulse wave Doppler, tissue Doppler 
and  two dimensional grey scale imaging in all conventional views, as recommended by the 
American Society of Echocardiography15. Loops of three consecutive cardiac cycles, with a 
minimum frame rate of 50s were stored offline, for subsequent analysis with a dedicated 
software package (EchoPAC version BT11, GE-Vingmed, Horton, Norway). LVEF, left 
ventricular end-systolic volume index (LVESVi) and end-diastolic volume index (LVEDVi) 
(corrected to body surface area of individual subjects) were calculated utilizing Simpson’s 
biplane method.  The wall motion score index (WMSI) was determined as previously 
described12. 
For speckle tracking analyses, the endocardium was manually traced at end systole to 
generate a segmented region of interest, the width of which was adjusted to include the 
thickness of the LV myocardium. Segmental motion was then automatically tracked 
throughout a cardiac cycle. Strain was defined as the change in the length of the segment 
studied, as a percentage of its final (end-diastolic) length, with  respect to the three orthogonal 
directions of tissue deformation (longitudinal, radial and circumferential, in  relation  to  the 
cardiac  axis);  strain  rate  (SR) was  defined  as  the  rate  at which  this  deformation occurs. 
Peak values were derived from strain-time and SR-time curves, respectively. Mean global 
longitudinal  strain/SR  were  derived  from  the  three individual apical  views  and  thus  
represent  triplanar  averages. Radial and circumferential function was studied as strain and 
SR (averaged from all segments) at the base, mid-ventricle and apex.  Twist mechanics were 
studied at the LV base and apex and the average peak rotation and rotation rate were 
determined from automatically generated curves. Counter-clockwise rotation, as observed at 
the apex,  was  expressed  as  a  positive  value,  whilst  basal  clockwise  rotation  was 
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expressed as negative  16. LV twist was defined as the net difference between peak apical and 
peak basal rotation, whereas LV torsion was defined  as  LV  twist,  normalized  for  LV  
diastolic  length,  as  elsewhere  described 16.  
Cardiovascular magnetic resonance imaging (CMR) imaging was performed both 
acutely and after 3 months in order to quantitate myocardial oedema via integrated estimates 
of T2-weighted signal intensity (T2 SI) within the entire left ventricle, as previously 
described12. 
A number of biochemical investigations were performed in order to quantitate the 
initial catecholamine stimulus towards development of TTC, together with the extent of 
inflammatory response and cellular damage. Furthermore, most of these investigations were 
repeated at 3 months’ follow-up. 
(a) Catecholamine release was measured via plasma metanephrine and normetanephrine 
concentrations13. 
(b) Inflammatory activation was quantitated via hs-CRP and NT-proBNP concentrations. 
(c) Extent of myocardial necrosis was quantitated via release of troponin T and creatine 
kinase to (CK). 
 We sought to evaluate patients’ quality of life as assessed by the Short Form health 
survey (SF36), completed at ≥ 3 months by 24 patients. The SF36 questionnaire includes a 
physical composite score (SF36-PCS), which was utilized for assessment of hypothesis 2. 
 The data were analysed using the SPSS version 20 software (SPSS, Chicago, Illinois, 
USA), and presented as mean ± 1SD unless otherwise specified.  To evaluate functional 
indices of recovery, three indices were chosen as potential markers of recovery of LV systolic 
function. These were (i) global longitudinal strain (GLS), (ii) longitudinal strain rate (LSR), 
and (iii) peak apical twist (AT). It was prospectively elected that correlations between 
recovery and ongoing inflammation would utilize whichever of these parameters displayed 
the most consistent impairment during recovery from TTC. As regards testing of hypothesis 
2, we elected to seek correlations between GLS at 3 months and SF36-PCS utilizing 
Pearson’s correlation and correlations with the total SF36 were also evaluated as a secondary 
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consideration. Comparisons between controls and TTC patients were performed utilizing the 
3-month TTC data. Methodology included non-paired t-tests or Wilcoxon signed rank tests 
for quantitative data and χ2 tests for categorical data. Correlations within the TTC group were 
performed via Pearson’s or Spearman’s rank correlation as appropriate.  
Results 
 TTC patients (n = 36) and controls (n = 19) were well matched for age and 
distribution of coronary risk factors (Table 1). Among the TTC cohort, 33% presented with S-
T elevation and all had abnormally elevated plasma troponin T (0.46 ± 0.39 mg/dl) and NT-
proBNP levels (7557 ± 8626 pg/ml). 75% of the TTC patients were treated with ACE 
inhibitors for at least the first 3 months post presentation. 
 Over the first 3 months of follow-up, all parameters of LV systolic function improved 
progressively (Table 2). For example, LVEF increased from 52 ± 14% at presentation to 60 
±7% (p = 0.003), with significant reductions in LV end-systolic and end-diastolic volumes. 
Furthermore, there was significant improvement in all rotational and longitudinal parameters 
measured (Table 2). Transmitral E/A ratio fell from 1.1 ± 0.5 to 0.9 ± 0.4 (p < 0.05). 
 Of three indices evaluated, in normal controls the greatest heterogeneity of data was 
seen with LV apical twist (SD 43% of mean) and the least with GLS (SD 8% of mean, see 
Table 2). GLS was therefore chosen as a primary basis for comparison between groups. On 
this basis, a study of the size of the current investigation had approximately 80% power to 
detect > 2% difference in GLS values between recovering TTC patients and controls at p < 
0.05. 
 The primary comparison related to echocardiographic deformational indices 
persisting in TTC patients at 3 months, as summarised in Table 2. 
All of the parameters evaluated were numerically lower in TTC patients than in control 
subjects, with inter-group differences ranging from 5 to 18%. However, only the differences 
in GLS at 3 months were statistically significant (p=0.003) (Figure 1). 
 GLS at 3 months was not significantly correlated with any indices of the acute TTC 
episode (plasma normetanephrine levels, troponin T, peak NT-proBNP levels, echo-derived 
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WMSI or extent of myocardial oedema on CMR)12. Correlations were also sought between 
markers of residual inflammation at 3 months and simultaneous GLS. For hs-CRP, there was 
no significant correlation; however residual NT-proBNP levels were directly correlated with 
GLS (r = 0.4, p = 0.03; Figure 2). No clinical or biochemical correlates were found to predict 
extent of improvement in GLS over 3 months. 
 There was also a significant correlation between SF36-PCS and GLS at 3 months (r = 
-0.41, p = 0.04; Figure 3).  
Discussion 
 The findings of the current investigation reveal that subtle but clinically relevant, 
impairment of LV systolic function, as measured by GLS, persists 3 months after an acute 
episode of TTC, despite normalisation of LVEF and of most other echocardiographic indices. 
The extent of impairment of GLS in individual patients was directly correlated with that of 
quality of life, as measured from SF36-PCS domain. Furthermore, there was a significant 
correlation in individual patients between extent of residual NT-proBNP elevation and that of 
GLS impairment. These data therefore add to previous evidence that cardiac recovery from 
TTC is substantially slower than was appreciated by original investigations, and provide the 
first evidence that residual symptoms in TTC reflect continued disease activity.  
 Although initially regarded as a relatively rare disorder of little prognostic 
importance, TTC is emerging as a relatively common cause of cardiac disability in aging 
women3,4. In spite of occasional mortality, especially due to early development of cardiogenic 
shock, the majority of patients appear to be at little risk of cardiac events (other than 
recurrence of TTC) thereafter. However, a consistent observation in large series has been of 
ongoing symptomatic status17; the issue is whether this reflects associated depressive status of 
many patients or whether it results from continued impairment of cardiac function. 
 There are several pieces of evidence that the slow resolution of symptoms after acute 
TTC episodes is not purely of psychosomatic origin. For example, we have previously 
demonstrated that 3 months post-acute episodes, plasma levels of BNP and NT-proBNP 
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remain elevated above population norms13. Furthermore, quantitation of myocardial oedema 
via T2-weighted CMR imaging reveals the presence of slowly resolving global changes, with 
persistent oedema at 3 months12. We have recently demonstrated myocardial energetic 
impairment both during the acute phase of TTC and persistent for at least 4 months thereafter 
18: this may indicate that energetic impairment parallels with myocardial inflammation. As 
BNP/NT-proBNP release appear to be inflammatory activation (rather than distensive) in 
origin13, the correlation between NT-proBNP and GLS at 3 months suggests that residual 
inflammation may contribute to this subtle impairment. 
 The finding that impairment of GLS at 3 months in individual patients correlates with 
that of SF36-PCS is of great importance. It can be argued on this basis that (1) continued 
impairment of quality of life long after acute TTC episodes represents (at least 
predominantly) the impact of ongoing myocardial dysfunction rather than purely emotional 
“strain” and (2) that the extent of impairment of GLS at 3 months is not purely an academic 
finding, but one of considerable clinical importance. Indeed, these data provide a basis for 
attempting to identify prospectively which TTC patients are likely to suffer ongoing 
impairment of LV function, as currently measured, and whether such impairment is 
potentially permanent. 
 The main conceptual limitation of the current study is that evaluation of the residual 
echocardiographic changes has been performed only at rest, under which conditions the 
abnormalities appear minor. On the other hand, most residual symptoms in this cohort of 
patients were of lassitude and exertional dyspnoea. Given the recent data show that TTC is 
associated with prolonged impairment of myocardial energetics18, it is certainly possible that 
contractile dysfunction may be accentuated during exercise. Furthermore, hypertension was 
marginally more common among TTC patients than controls, which could contribute to GLS 
differences. 
 To date, therapeutic interventions in TTC have been nonspecific and generally 
transient: for example the use of early anticoagulation to prevent LV mural thrombosis. The 
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current findings argue for the development of strategies to accelerate recovery of LV function 
post TTC, and therefore ultimately for better understanding of the pathogenesis of this 
extraordinary condition. 
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Legends for figures: 
Figure 1: Time course of recovery of LV function, expressed in terms of mean absolute 
values (left hand site) and as percentage of control group-derived normal values (right hand 
side), for global longitudinal strain (A and B), longitudinal strain rate (C and D), and apical 
twist (E and F). 
Figure 2: Relationship between global longitudinal strain at 3 months and simultaneous NT-
proBNP concentrations (r = 0.4, p = 0.03). 
Figure 3: Relationship between residual global longitudinal strain and SF36-PCS at ≥ 3 
months (r = -0.41, p = 0.04). 
 
 
 
 
 
 
 
 
 
 
 
